- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01559246
True Continuous ECG Monitoring (TCEM Study) (TCEM)
April 17, 2019 updated by: iRhythm Technologies, Inc.
Comparison of Short Term Holter Monitoring vs. Long Term Zio(R)Patch True Continuous ECG Monitoring (TCEM Study)
The purpose of this study is to compare short term (up to 48 hours) traditional cardiac rhythm monitoring using a standard ambulatory Holter monitor versus long term (up to 14 days), continuous ambulatory cardiac rhythm monitoring using a new device cleared by the FDA (Zio® Patch), iRhythm Technologies, Inc., San Francisco CA) in patients with suspected cardiac arrhythmias.
Study Overview
Status
Completed
Conditions
Detailed Description
This is a prospective, observational study of patients seen in the Holter lab at Scripps Green Hospital and other Scripps Clinic locations.
Only patients who have indications for traditional cardiac rhythm monitoring will be enrolled in the study.
Patients 18 years or older with suspected arrhythmias capable of providing informed consent will wear both a traditional Holter monitor for up to 48 hours and a Zio® Patch for up to 14 days.
Both devices will be initiated at the same time as they do not interfere with one another.
This will also allow a direct comparison of the same initial up to 24 hour monitoring period between the two devices.
As the Zio® Patch is worn for up to 14 days instead of only 24 hours, it will be assessed if in the physician's opinion (referring physician), waiting for the extended time hinders being able to provide medical care and/or diagnosis for the patient.
Study Type
Observational
Enrollment (Actual)
150
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
La Jolla, California, United States, 92037
- Scripps Health
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients 18 years of age of greater with suspected arrhythmias.
Description
Inclusion Criteria:
- Are being seen in the outpatient office for evaluation, treatment, or follow-up of arrhythmias;
- Have a medical history for which ascertaining whether asymptomatic arrhythmias is occurring could be helpful in their treatment plan;
- Are capable of giving informed consent; assessed by the investigator or the Study Coordinator;
- Are 18 years of age or older;
- Able to comply with long term continuous monitoring ECG device.
Exclusion Criteria:
- Have known skin allergies, conditions, or sensitivities (e.g. allergy to adhesives, psoriasis) as the Zio(R)Patch should not be used on patients with known skin allergies, conditions, or sensitivities; or
- Are receiving pacing therapy (e.g., from a pacemaker); or
- Are anticipated to receive or require external cardiac defibrillation during the monitoring period; or
- Are anticipated to be exposed to high frequency surgical equipment during the monitoring period.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Cardiac Arrhythmia
Subjects 18 years of age or greater that have indications for traditional cardiac(Holter) monitoring.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Arrhythmia detection for Zio® patch and the traditional ambulatory Holter monitor.
Time Frame: Up to 14 days.
|
Data will be examined to determine the difference in the number of 6 types of arrhythmias detected at maximum observation times of 14 days and 24 hours respectively.
In comparing the difference of the number of arrhythmias for the Zio® Patch and the Holter data, we are expecting a skewed distribution of the differences and will use a paired Wilcoxon Signed Rank Test since the normality assumption is not met for a paired t-test.
If the difference is significantly greater than zero, there is evidence that the Zio® Patch is an improvement in this sample.
|
Up to 14 days.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Subjects ease in comfort for the Zio® Patch and the traditional ambulatory Holter monitor.
Time Frame: Up to14 days.
|
Subjects will be given surveys to complete at different time points.
Surveys to include questions assessing subjects preference in devices.
McNemar's Test will be used to examine if the responses for ease of wear was different between the Zio® Patch and the Holter.
Comparing both devices when the Holter is returned in the first 24/48 hours, and comparing the Holter at 24/48 hours and the Zio® Patch at total observation (up to 14 days).
McNemar's Test will be used to compare if the patient would use the Zio® Patch again and if they would use the Holter.
|
Up to14 days.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2012
Primary Completion (ACTUAL)
November 1, 2012
Study Completion (ACTUAL)
December 1, 2012
Study Registration Dates
First Submitted
March 9, 2012
First Submitted That Met QC Criteria
March 19, 2012
First Posted (ESTIMATE)
March 21, 2012
Study Record Updates
Last Update Posted (ACTUAL)
April 18, 2019
Last Update Submitted That Met QC Criteria
April 17, 2019
Last Verified
April 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- iRT-001-2012
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiac Arrhythmia
-
Medical University of LodzNot yet recruitingCardiac Arrhythmia | Supraventricular ArrhythmiaPoland
-
Myant Medical Corp.Partners in Advanced Cardiac EvaluationRecruiting
-
Myant Medical Corp.Partners in Advanced Cardiac EvaluationCompleted
-
New York Institute of TechnologyCompleted
-
Kansas City Heart Rhythm InstituteBiosense Webster, Inc.TerminatedArrhythmia, CardiacUnited States
-
Paris Sudden Death Expertise CenterHospices Civils de Lyon; University Hospital, Strasbourg, France; University... and other collaboratorsRecruitingDefibrillators, Implantable | Sudden Cardiac Death Due to Cardiac ArrhythmiaFrance
-
Children's National Research InstituteNational Institutes of Health (NIH)CompletedVentricular Tachycardia | Cardiac ArrhythmiaUnited States
-
Imperial College LondonImperial College Healthcare NHS TrustRecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Fibrillation, Persistent | Cardiac ArrhythmiaUnited Kingdom
-
Adana City Training and Research HospitalCompleted
-
SanofiCompletedVentricular Arrhythmia | Arrhythmia ProphylaxisNetherlands, Spain, Belgium, Japan, Finland, Chile, Australia, United States, Argentina, Canada, Czech Republic, Denmark, France, Germany, Hungary, Israel, Italy, Mexico, Norway, Poland, Portugal, Russian Federation, Slovakia, South Africa and more